ANDOVER, Mass., July 15, 2015 /PRNewswire/ -- With more than
15 million adults in the U.S. living with chronic obstructive
pulmonary disease (COPD) and hospitals under increasing pressure to
adhere to 30-day COPD readmissions standards, new research
published in the Journal of Clinical Sleep Medicine
highlights non-invasive ventilation as a key part of a
multi-faceted intervention approach to successfully reduce
readmission rates among COPD patients. The study, funded and
co-authored by Royal Philips
(NYSE: PHG, AEX: PHIA), evaluated COPD patients who were
hospitalized two or more times within a year and transitioned to a
COPD patient management program, which included treating those same
patients with noninvasive positive pressure ventilation (NIPPV).
The results of the study showed that the readmission rate was
reduced by 97 percent during the subsequent 12 months. The study
used Philips Respironics Trilogy 100 to deliver the NIPPV therapy
to the study patients.
In the U.S., costs for hospital stays for patients with COPD as
a principal diagnosis has been projected to be approximately
$29.5 billion.1 The
readmission rate within 30 days of discharge for patients with COPD
has been reported to be as high as 22.6%.2 In this
study, the proportion of COPD patients who were readmitted on two
or more occasions decreased from 100% (397 of 397) in the year
prior to initiation of intervention to 2.2% (9 of 397) in the
following year.
"The results of this study indicate that Philips Trilogy with an
advanced mode of ventilation AVAPs-AE therapy – in combination with
respiratory therapist-led care, medication reconciliation and
adequate provision of oxygen therapy – assisted in stabilizing the
respiratory condition of patients with COPD," said Amy Day, RRT, Director of Ventilation Management
of Barnes Healthcare Services. "Such better management of the COPD
condition allows health systems to not only significantly reduce
readmissions and the associated high costs, but also improve the
quality of life for some of its most complex patients."
The study, entitled "Retrospective Assessment of Home
Ventilation to Reduce Rehospitalization in Chronic Obstructive
Pulmonary Disease" and authored by Steven
Coughlin, PhD, Wei Liang, PhD
and Sairam Parthasarathy, MD,
examined 397 patients who had all been hospitalized at least twice
in a single year with an acute COPD exacerbation. Each patient was
prescribed a Trilogy ventilator manufactured by Philips
Respironics for home use. Continued in home care consisted of
medication management, oxygen therapy, patient education and
ongoing respiratory therapist care in the home.
"This study holds promise in how a multi-faceted intervention
could assist health systems in significantly improving the care of
the patients with advanced stage COPD in their home," said
Sairam Parthasarathy, MD, Professor
of Medicine and Director of the Center for Sleep Disorders at
Banner – University Medical Center Tucson. "The results indicate
that patients placed on this advanced mode of non-invasive
ventilation, combined with an in-home care program, can reduce
hospitalizations and subsequently reduce healthcare utilization.
This study is a good foundation to build from and to further
validate."
Connected COPD Care
With more treatments available to them today than ever before,
COPD patients are living longer after diagnosis. Home, portable
non-invasive ventilators help homecare providers manage more
patients with fewer resources, while allowing patients to live
healthy lives at home.
"The results of this are more critical now more than ever, given
the industry's increased focus on the high cost of chronic diseases
and the need to reduce the re-hospitalization of COPD patients,"
said Eli Diacopoulos, Vice President
and General Manager, Philips Respironics. "The use of Trilogy in
this COPD management program is just one example of our ability to
work with an innovative homecare provider partner to achieve a new
kind of COPD care management model that connects and supports the
clinician, caregiver, home care provider and the patient at every
point along the patient care path."
Philips Respironics is committed to innovating patient-centered
COPD care management models. Philips is currently piloting a COPD
care model that utilizes Bluetooth-enabled Trilogy devices and a
tablet application tool to optimize clinician, caregiver and
homecare provider coordination. This pilot is Philips Respironics'
next step toward connected homecare solutions for respiratory
patients.
For more information on Philips' portfolio of connected sleep
and respiratory care solutions, follow @PhilipsResp and the Philips
Respironics Facebook page.
For further information, please contact:
Alicia Cafardi
Philips
alicia.cafardi@philips.com
724-387-4439
About Royal Philips:
Royal Philips (NYSE: PHG, AEX: PHIA)
is a diversified health and well-being company, focused on
improving people's lives through meaningful innovation in the areas
of Healthcare, Consumer Lifestyle and Lighting. Headquartered in
the Netherlands, Philips posted
2014 sales of EUR 21.4 billion and
employs approximately 108,000 employees with sales and services in
more than 100 countries. The company is a leader in cardiac care,
acute care and home healthcare, energy efficient lighting solutions
and new lighting applications, as well as male shaving and grooming
and oral healthcare. News from Philips is located
at www.philips.com/newscenter.
1 Confronting COPD in America, 2000. Schulman, Ronca
and Bucuvalas, Inc. (SRBI) Funded by Glaxo Smith Kline
2 Jencks SF, Williams MV, Coleman EA. Rehospitalizations
among patients in the Medicare fee-for-service program. N Engl J
Med. April 2
2009;360(14):1478-1428.
Logo -
http://photos.prnewswire.com/prnh/20140122/NE50581LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/new-data-published-in-journal-of-clinical-sleep-medicine-shows-philips-trilogy-and-patient-management-program-helps-reduce-copd-readmissions-by-97-percent-300113517.html
SOURCE Royal Philips